CD34 and chronic graft versus host disease: Notably, despite younger donor age, the higher CD34+ cell dose group exhibited increased rates of chronic GVHD and NRM, which contrasts with several recent studies suggesting that younger donors are associated with a lower risk of these complications [22, 23].